Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Goals and Barriers to Effective Psoriasis Care
Bruce Strober, Joelle M. van der Walt, April W. Armstrong, et al.
Dermatology and Therapy (2018) Vol. 9, Iss. 1, pp. 5-18
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Evolving therapeutic goals in ulcerative colitis: towards disease clearance
Silvio Danese, Giulia Roda, Laurent Peyrin‐Biroulet
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 17, Iss. 1, pp. 1-2
Closed Access | Times Cited: 124
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 63
Inflammatory memory in psoriasis: From remission to recurrence
Luc Francis, Francesca Capon, Catherine Smith, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 42-50
Open Access | Times Cited: 12
Long-term topical management of psoriasis: the road ahead
Siegfried Segaert, Piergiacomo Calzavara‐Pinton, P. de la Cueva, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 1, pp. 111-120
Open Access | Times Cited: 55
Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 6, pp. 1094-1105
Open Access | Times Cited: 51
Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy
Evangelia Sarandi, Sabine Krueger‐Krasagakis, Dimitris Tsoukalas, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 17
<p>Cyclodextrin-Modified CeO<sub>2</sub> Nanoparticles as a Multifunctional Nanozyme for Combinational Therapy of Psoriasis</p>
Lingyun Wu, Guoyan Liu, Wenyu Wang, et al.
International Journal of Nanomedicine (2020) Vol. Volume 15, pp. 2515-2527
Open Access | Times Cited: 41
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)
Matthias Augustin, Rachel Sommer, E. Daudén, et al.
BMJ Open (2023) Vol. 13, Iss. 2, pp. e060536-e060536
Open Access | Times Cited: 16
Disease clearance in ulcerative colitis: A new therapeutic target for the future
Syed Adeel Hassan, Neeraj Kapur, Fahad Sheikh, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 13, pp. 1801-1809
Open Access | Times Cited: 5
Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey
Joe Gorelick, David Shrom, Kiran Sikand, et al.
Dermatology and Therapy (2019) Vol. 9, Iss. 4, pp. 785-797
Open Access | Times Cited: 39
Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
A.Y. Finlay, Pavel V. Chernyshov, L. Tomás-Aragonés, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 318-328
Open Access | Times Cited: 33
Efficacy of Therapy with the Interleukin-23 Inhibitor а Guselkumab and Quality of Life Indicators in Patients with Psoriasis
И. С. Владимирова, Л. С. Круглова
Effective Pharmacotherapy (2024) Vol. 20, Iss. 1, pp. 18-26
Open Access | Times Cited: 3
Disease clearance in ulcerative colitis: What is it? What does it involve? How do we translate it into Spanish?
Laura Ramos, Ignacio Marín‐Jiménez
Gastroenterología y Hepatología (English Edition) (2025), pp. 502281-502281
Closed Access
High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Kave Shams, Jennifer Montgomery, J. E. Morley, et al.
Dermatology and Therapy (2025)
Open Access
Remote Monitoring of Psoriasis: Comparing Care Models and Evaluating Quality of Life Outcomes – a mixed methods study (Preprint)
Jana Arsenjeva, Priit Kruus, Riina Hallik, et al.
Journal of Medical Internet Research (2025)
Open Access
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Kristian Reich, April W. Armstrong, Peter Foley, et al.
American Journal of Clinical Dermatology (2020) Vol. 21, Iss. 6, pp. 881-890
Closed Access | Times Cited: 26
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis
Paolo Gisondi, Davide Geat, Andrea Conti, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 6, pp. 591-598
Closed Access | Times Cited: 25
Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study
David Gleeson, Maneeha Naveed, Lucy Moorhead, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 243-251
Open Access | Times Cited: 3
Experience of living with psoriasis in Brazil: a Global Psoriasis Atlas online survey
Jaquelini Barboza da Silva, Alison K. Wright, André Vicente Esteves de Carvalho, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 3
Treat to target or ‘treat to clear’ in inflammatory bowel diseases: one step further?
Arianna Dal Buono, Giulia Roda, Marjorie Argollo, et al.
Expert Review of Gastroenterology & Hepatology (2020) Vol. 14, Iss. 9, pp. 807-817
Closed Access | Times Cited: 22
Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab
Katherine Houghton, Dhaval Patil, Braulio Gómez, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1373-1384
Open Access | Times Cited: 19
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda Stein Gold, Jerry Bagel, Stephen K. Tyring, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 5, pp. 540-552
Open Access | Times Cited: 8
Implementing well‐being in the management of psoriasis: An expert recommendation
Rachel Sommer, Ulrich Mrowietz, Kristian Gaarn du Jardin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 2, pp. 302-310
Open Access | Times Cited: 7
Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)
Kenneth B. Gordon, Richard B. Warren, Alice B. Gottlieb, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 4, pp. 652-662
Open Access | Times Cited: 20
Small molecules under development for psoriasis: on the road to the individualized therapies
Claudia Cervantes‐Durán, Velázquez-Hernández María-Elena, Josue Valentin‐Escalera, et al.
Archives of Dermatological Research (2020) Vol. 312, Iss. 9, pp. 611-627
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top